Agenus Inc.

Agenus (AGEN) filed an 8-K under Items 1.01, 2.03, and 3.02, disclosing entry into a material definitive agreement, creation of a direct financial obligation, and unregistered securities issuance. The event occurred on August 12, 2026. No specific deal terms or dollar amounts were included in the available excerpt. Agenus is a clinical-stage immuno-oncology company.

Agenus Inc. (AGEN) filed an 8-K on August 13, 2026 (event date August 10) under Item 5.02, reporting a change in the company's officers or directors. The excerpt contains only the cover page; the identity of the departing or appointed individual and their role are in the filing body. Item 5.02 changes are common for clinical-stage biotechs undergoing strategic transitions. Agenus is an immuno-oncology company focused on antibody discovery and cancer immunotherapy.

Agenus Inc. (AGEN) disclosed that on August 5, 2026, its Board expanded from six to seven directors and appointed Marco Tullio Marcucci as a Class II director, filling the new vacancy effective immediately. Mr. Marcucci was also appointed to the Corporate Governance and Nominating Committee. He will serve until Agenus's 2029 annual meeting of stockholders. No compensation details were provided in this filing.

Agenus Inc. filed a new Form S-3 shelf registration on August 7, 2026 to offer common stock, preferred stock, debt securities, warrants, or units from time to time on a delayed or continuous basis under Rule 415. No specific dollar amount or immediate offering size is disclosed in the filing excerpt. CEO and Chairman Garo Armen is the named company representative, with Latham & Watkins serving as legal counsel. This is a routine shelf registration providing future capital-raising flexibility for the clinical-stage immuno-oncology company.

Agenus Inc. (AGEN) filed a Form S-3 shelf registration statement on July 17, 2026, to register securities for future offering on a delayed or continuous basis under Rule 415. The excerpt covers only the cover page boilerplate — no total offering size, security type mix, or use-of-proceeds details are disclosed. Agenus is classified as an accelerated filer and smaller reporting company. This is a routine shelf registration that provides capital-raising flexibility but represents no immediate dilution.

Agenus Inc. entered into a Securities Purchase Agreement on July 13, 2026 for a private placement with institutional and accredited investors, closing expected July 15, 2026. The company will issue up to 23,035,227 shares (or pre-funded warrants at $0.01/share exercise price), plus Series A Warrants for ~21.1 million shares at $4.02 and Series B Warrants for ~33.8 million shares at $5.03, all at a combined effective purchase price of $3.69/share. Gross proceeds are approximately $85 million upfront, with up to $255 million more upon full warrant exercise. Highly dilutive capital raise — adds roughly 77 million initial shares and up to 55 million additional on warrant conversion — reflecting significant financing pressure.

Agenus Inc. executed an amendment with existing noteholders on June 29, 2026, extending the maturity of $5.09 million in 2015 senior subordinated notes by 8 months to February 18, 2027, and extending the expiration of existing A, B, and C Warrants to June 25, 2031. Additionally, new 2026 D Warrants to purchase 56,525 shares of common stock at $3.25/share (expiring June 25, 2031) were issued to certain noteholders; those shares are to be registered for resale within 90 days. Small-scale debt and warrant management transaction — the 8-month note extension defers a near-term maturity with minimal dilution (~57K new warrants), reflecting Agenus's ongoing capital management.

Agenus Inc. held its 2026 Annual Meeting on June 16, 2026 with 65.24% of shares represented. Shareholders elected Class II directors Garo Armen and Jennifer Buell, approved increases to the ESPP (150K to 200K shares) and 2019 Equity Incentive Plan (+5 million shares), approved a one-time stock option exchange program allowing directors and executives to swap underwater options for new grants with premium strike prices, and ratified KPMG LLP as auditor. The stock option exchange program is the most notable outcome — it effectively reprices executive and director awards, signaling existing strike prices are materially above the current share price.